Revisiting Interleukin-12 as a Cancer Immunotherapy Agent

被引：65

作者：

Berraondo, Pedro ^{[1
,2
,3
]}

Etxeberria, Inaki ^{[1
,2
]}

Ponz-Sarvise, Mariano ^{[2
,4
,5
]}

Melero, Ignacio ^{[1
,2
,3
,4
,5
]}

机构：

[1] Univ Navarra, Ctr Appl Med Res CIMA, Immunol & Immunotherapy Program, Pamplona, Spain

[2] Navarra Inst Hlth Res IdiSNA, Pamplona, Spain

[3] Ctr Invest Biomed Red Canc CIBERONC, Madrid, Spain

[4] CUN, Dept Oncol, Pamplona, Spain

[5] CUN, Dept Immunol, Pamplona, Spain

来源：

CLINICAL CANCER RESEARCH | 2018年 / 24卷 / 12期

关键词：

T-CELL TRANSFER; DOXORUBICIN; THERAPY;

D O I：

10.1158/1078-0432.CCR-18-0381

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

IL12 antitumor activities are mediated by the activation of T and natural killer (NK) lymphocytes to produce IFNg. Systemically, recombinant IL12 has a narrow therapeutic window that favors local delivery, for instance, by gene therapy approaches. IL12 is a powerful partner in immunotherapy combinations with checkpoint inhibitors and adoptive T-cell transfer. (C) 2018 AACR.

引用

页码：2716 / 2718

页数：3

共 11 条

[1] Doxorubicin Eliminates Myeloid-Derived Suppressor Cells and Enhances the Efficacy of Adoptive T-Cell Transfer in Breast Cancer
Alizadeh, Darya
Trad, Malika
Hanke, Neale T.
Larmonier, Claire B.
Janikashvili, Nona
Bonnotte, Bernard
Katsanis, Emmanuel
Larmonier, Nicolas
[J]. CANCER RESEARCH, 2014, 74 (01) : 104 - 118
[2] Lineage-specific requirement for signal transducer and activator of transcription (Stat)4 in interferon γ production from CD4+ versus CD8+ T cells
Carter, LL
Murphy, KM
[J]. JOURNAL OF EXPERIMENTAL MEDICINE, 1999, 189 (08) : 1355 - 1360
[3] Caspase-dependent immunogenicity of doxorubicin-induced tumor cell death
Casares, N
Pequignot, MO
Tesniere, A
Ghiringhelli, F
Roux, S
Chaput, N
Schmitt, E
Hamai, A
Hervas-Stubbs, S
Obeid, M
Coutant, F
Métivier, D
Pichard, E
Aucouturier, P
Pierron, G
Garrido, C
Zitvogel, L
Kroemer, G
[J]. JOURNAL OF EXPERIMENTAL MEDICINE, 2005, 202 (12) : 1691 - 1701
[4] Enhanced antitumor effects by combining an IL-12/anti-DNA fusion protein with avelumab, an anti-PD-L1 antibody
Fallon, Jonathan K.
Vandeveer, Amanda J.
Schlom, Jeffrey
Greiner, John W.
[J]. ONCOTARGET, 2017, 8 (13) : 20558 - 20571
[5] Enhancement of adoptive T cell transfer with single low dose pretreatment of doxorubicin or paclitaxel in mice
Hsu, Fei-Ting
Chen, Tzu-Chun
Chuang, Hui-Yen
Chang, Ya-Fang
Hwang, Jeng-Jong
[J]. ONCOTARGET, 2015, 6 (42) : 44134 - 44150
[6] T-cell Homing Therapy for Reducing Regulatory T Cells and Preserving Effector T-cell Function in Large Solid Tumors
Hu, Jiemiao
Sun, Chuang
Bernatchez, Chantale
Xia, Xueqing
Hwu, Patrick
Dotti, Gianpietro
Li, Shulin
[J]. CLINICAL CANCER RESEARCH, 2018, 24 (12) : 2920 - 2934
[7] Tumor-Specific CD8+ T Cells Expressing Interleukin-12 Eradicate Established Cancers in Lymphodepleted Hosts
Kerkar, Sid P.
Muranski, Pawel
Kaiser, Andrew
Boni, Andrea
Sanchez-Perez, Luis
Yu, Zhiya
Palmer, Douglas C.
Reger, Robert N.
Borman, Zachary A.
Zhang, Ling
Morgan, Richard A.
Gattinoni, Luca
Rosenberg, Steven A.
Trinchieri, Giorgio
Restifo, Nicholas P.
[J]. CANCER RESEARCH, 2010, 70 (17) : 6725 - 6734
[8] Adenoviral gene transfer of interleukin 12 into tumors synergizes with adoptive T cell therapy both at the induction and effector level
Mazzolini, G
Qian, C
Narvaiza, I
Barajas, M
Borrás-Cuesta, F
Xie, XM
Duarte, M
Melero, I
Prieto, J
[J]. HUMAN GENE THERAPY, 2000, 11 (01) : 113 - 125
[9] Virotherapy with a Semliki Forest Virus-Based Vector Encoding IL12 Synergizes with PD-1/PD-L1 Blockade
Quetglas, Jose I.
Labiano, Sara
Aznar, M. Angela
Bolanos, Elixabet
Azpilikueta, Arantza
Rodriguez, Inmaculada
Casales, Erkuden
Sanchez-Paulete, Alfonso R.
Segura, Victor
Smerdou, Cristian
Melero, Ignacio
[J]. CANCER IMMUNOLOGY RESEARCH, 2015, 3 (05) : 449 - 454
[10] Gene therapy of cancer based on interleukin 12
Sangro, B
Melero, I
Qian, C
Prieto, J
[J]. CURRENT GENE THERAPY, 2005, 5 (06) : 573 - 581

← 1 2 →